Download or read book Novel cancer related biomarkers written by Viktor Magdolen and published by Walter de Gruyter. This book was released on 2012-12-06 with total page 242 pages. Available in PDF, EPUB and Kindle. Book excerpt: Various KLK proteins and their encoding genes have attracted increased attention among scientists and clinicians worldwide since they represent very interesting and functionally distinct biomarkers, particularly, in cancer. This book reviews the role of kallikrein-related peptidases (KLKs) in a wide range of cancers, including lung, prostate, breast and ovarian cancer. It provides clinicians, physician scientists and researchers with a comprehensive overview on the clinical relevance of KLK expression in various malignancies.
Download or read book The Handbook of Biomarkers written by Kewal K. Jain and published by Springer Science & Business Media. This book was released on 2010-02-06 with total page 509 pages. Available in PDF, EPUB and Kindle. Book excerpt: Of the thousands of biomarkers that are currently being discovered, relatively few are being validated for further applications, and the potential of a biomarker can be quite difficult to evaluate. To aid in this imperative research, Dr. Kewal K. Jain’s Handbook of Biomarkers thoroughly describes many different types of biomarkers and their discovery using various "-omics" technologies, such as proteomics and metabolomics, along with the background information needed for the evaluation of biomarkers as well as the essential procedures for their validation and use in clinical trials. With biomarkers described first according to technologies and then according to various diseases, this detailed book features the key correlations between diseases and classifications of biomarkers, which provides the reader with a guide to sort out current and future biomarkers. Comprehensive and cutting-edge, The Handbook of Biomarkers serves as a vital guide to furthering our understanding of biomarkers, which, by facilitating the combination of therapeutics with diagnostics, promise to play an important role in the development of personalized medicine, one of the most important emerging trends in healthcare today.
Download or read book Handbook of Therapeutic Biomarkers in Cancer written by Sherry X. Yang and published by CRC Press. This book was released on 2021-02-01 with total page 678 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.
Download or read book Novel Biomarkers in the Continuum of Breast Cancer written by Vered Stearns and published by Springer. This book was released on 2016-03-17 with total page 291 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment(s) for individual patients.
Download or read book Biomarkers for Immunotherapy of Cancer written by Magdalena Thurin and published by Humana. This book was released on 2019-09-10 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides the immune oncology (IO) community with a deeper understanding of the scope of the biomarker methods to potentially improve the outcome from immunotherapy. The editors secured the input from experts in the field dedicated to translating scientific research from bench to bedside was submitted. The book provides not only details about the technical, standardization and interpretation aspects of the methods but also introduces the reader to the background information and scientific justification for selected biomarkers and assays. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Download or read book Biomarkers in Breast Cancer written by Giampietro Gasparini and published by Springer Science & Business Media. This book was released on 2008-01-17 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Download or read book Role of Biomarkers in Medicine written by Mu Wang and published by BoD – Books on Demand. This book was released on 2016-08-17 with total page 262 pages. Available in PDF, EPUB and Kindle. Book excerpt: The use of biomarkers in basic and clinical research has become routine in many areas of medicine. They are accepted as molecular signatures that have been well characterized and repeatedly shown to be capable of predicting relevant disease states or clinical outcomes. In Role of Biomarkers in Medicine, expert researchers in their individual field have reviewed many biomarkers or potential biomarkers in various types of diseases. The topics address numerous aspects of medicine, demonstrating the current conceptual status of biomarkers as clinical tools and as surrogate endpoints in clinical research. This book highlights the current state of biomarkers and will aid scientists and clinicians to develop better and more specific biomarkers for disease management.
Download or read book Advances in Cancer Biomarkers written by Roberto Scatena and published by Springer. This book was released on 2015-11-03 with total page 361 pages. Available in PDF, EPUB and Kindle. Book excerpt: At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
Download or read book Predictive Biomarkers in Oncology written by Sunil Badve and published by Springer. This book was released on 2018-12-06 with total page 642 pages. Available in PDF, EPUB and Kindle. Book excerpt: “Precision/personalized or stratified medicine” refers to the tailoring of medical treatment or drug administration to the individual characteristics of each patient treatment. It does not literally mean that a pharmaceutical company makes a drug for an individual patient for consumption and treatment but rather means the ability to stratify (or classify) individuals into sub-populations that differ in their responsiveness to a specific drug. A marker that provides information on the likely response to therapy, i.e., either in terms of tumor shrinkage or survival of the patient is termed “predictive biomarker”. Despite their promise in precision medicine and the explosion of knowledge in this area, there is not a single source on this subject that puts all this evidence together in a concise or richly illustrated and easy to understand manner. This book provides a collection of ingeniously organized, well-illustrated and up-to-date authoritative chapters divided into five sections that are clear and easy to understand. Section one provides an overview of biomarkers, introduces the basic terminologies, definitions, technologies, tools and concepts associated with this subject in the form of illustrations/graphics, photographs and concise texts. Several recent biomarker endeavors that have been initiated and funded by the National Cancer Institute, National Institutes of Health, FDA and other International organizations are presented. Section two involves the signaling pathways controlling cell growth and differentiation altered in cancer. This section analyzes how predictive biomarkers are altered (expressed or amplified) across cancer types. Section three explores how predictive biomarkers play a role in patient stratification and tailored treatment in relationship to specific cancers. In addition, it includes discussion on the various precision medicine initiatives that are going on across the globe (e.g. TARGET, NCI-MATCH, BATTLE, SHIVA, etc.). Section four discusses: (a) how pharmaceutical companies validate predictive biomarker assays and accompanying companion diagnostics either internally or externally with partner companies such as central laboratories or clinical research organizations, and (b) how predictive biomarker tests fall under the oversight of US FDA, Centers for Medicare & Medicaid Services (CMS) and state laws. Section five wraps up novel agents and targets that are being used as targets for cancer therapeutics. The biomarkers associated with these protocols will also be presented. Throughout the book, sidebars, special interest boxes and illustrations are used to explain terms that are either newly introduced, uncommon, or specialized. Predictive Biomarkers in Oncology will serve as a definitive guide for practicing pathologists, oncologists, basic researchers, and personnel in the pharmaceutical or diagnostic industry interested in learning how “predictive biomarkers” are used in precision cancer therapy.
Download or read book Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease written by Institute of Medicine and published by National Academies Press. This book was released on 2010-06-25 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
Download or read book Biomarkers in Cancer Screening and Early Detection written by Sudhir Srivastava and published by John Wiley & Sons. This book was released on 2017-06-05 with total page 338 pages. Available in PDF, EPUB and Kindle. Book excerpt: Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers Provides immediately actionable information and hopefully also inspiration to move discovery and clinical application forward Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers
Download or read book Biomarkers in Carcinoma of Unknown Primary written by Sulen Sarioglu and published by Springer Nature. This book was released on 2022-01-01 with total page 468 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to examine all immunohistochemical and molecular pathological biomarkers that can be useful and effective in patient diagnosis, prognosis and treatment decision, especially when faced with a carcinoma of unknown primary. For this purpose, epithelial malignancies of all systems and related biomarkers are examined one by one, and to look at the subject through the metastatic regions window, biomarkers that can be used to determine the primary focus for carcinomas seen in the areas most frequently metastasized are emphasized. With this bi-directional perspective, the reader is able to find biomarkers of any type of carcinoma on a system basis, as well as access to which biomarkers can be used when faced with a metastatic carcinoma. The importance of biomarkers in patient follow-up and treatment is also conveyed through the clinician's eye, and so biomarkers are handled with a holistic approach in all aspects. This book primarily targets pathologists, as well as clinicians (oncologists and surgeons) who manage cancer patients.
Download or read book Novel biomarkers in tumor immunity and immunotherapy written by Takaji Matsutani and published by Frontiers Media SA. This book was released on 2024-07-26 with total page 343 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-PD-L1 antibodies are highly effective against many types of cancer, yet durable responses are limited to a subset of patients highlighting the need for the development of effective biomarkers to predict prognosis and efficacy. Currently, PD-L1 expression in tumors, microsatellite instability (MSI) or mismatch repair deficiency (dMMR), and tumor mutation burden (TMB) are known as biomarkers for cancer immunotherapy but are not sufficient. Combination therapy with immune checkpoint inhibitors and chemotherapy or radiation therapy, as well as diverse therapies targeting intra-tumoral regulatory T cells have been described, but there are currently no unifying biomarkers that are applicable to clinically, a simple, fast, non-invasive method that can yield biomarkers of disease with a minimal adverse effect on patients is desirable. Recent findings suggest that the balancing of effector T cells and regulatory cells in the tumor microenvironment is associated with cancer progression and prognosis. Cells and molecules involved in the control of cancer are complex, and a better understanding of the tumor immune environment will lead to the development of truly effective biomarkers. This topic will focus on novel biomarkers that predict efficacy, prognosis, or the development of adverse events in various cancer immunotherapies, and extensive basic research leading to the development of biomarkers. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic. We expect a wide range of research, not only in serology, genetics, and immunocytochemistry but also in bacterial flora. Research on the development of novel assays and bioinformatics methods is also welcome: • Non-invasive biomarkers for cancer immunotherapy. • Bulk RNA-seq, scRNA-seq, or Rep-seq methods. • Correlation of tumor immune cells with gut microbiota in tumor immunotherapy. • Impact of Teff and Treg balance in the tumor microenvironment on tumor prognosis. • Inflammatory and immune signatures associated with drug response versus resistance in cancer.
Download or read book Identifying Novel Biomarkers in Bladder Cancer 2nd edition written by Thornsten Ecke and published by Frontiers Media SA. This book was released on 2023-07-18 with total page 262 pages. Available in PDF, EPUB and Kindle. Book excerpt: Bladder cancer is one of the most common urological diseases with a high mortality rate and poor prognosis. It is currently ranked as the 10th most common malignancy worldwide. The majority of bladder cancer patients have been found to be diagnosed with non-muscle invasive bladder cancer (NMIBC) and the remaining, are diagnosed with muscle-invasive bladder cancer (MIBC). Although there have been advances in the treatment and therapies provided for bladder cancer patients, the survival rate remains low, primarily due to recurrence and metastasis of the disease following treatment. Surgical treatment is currently the most common form including radical cystectomy which is the standard form of treatment combined with neoadjuvant chemotherapy. However, the 5-year overall survival rate is 50%. Therefore, further studies are required to understand the molecular mechanisms involved in the progression of bladder cancer and identify novel biomarkers to act as a diagnostic tool for patients. There have been many studies involving the detection of biomarkers in bladder cancer in addition to monitoring disease recurrence to understand the impact and predict potential outcomes. A variety of urine biomarkers have been developed to detect bladder cancer and prognostic risk stratification including mutational DNA and the levels of RNA expression. Circulating tumor cells have also been identified as a potential biomarker for bladder cancer patients. However, there are significant challenges as bladder cancer has demonstrated high levels of cellular and molecular heterogeneity and some markers do not have sufficient sensitivity for accurate detection. Therefore, further studies are required to continue to identify new novel biomarkers for bladder cancer. The aim of this Research Topic is to discuss novel biomarkers in bladder cancer and how it impacts the disease progression and the survival rate for bladder cancer patients.
Download or read book Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy volume II written by and published by Frontiers Media SA. This book was released on 2024-01-10 with total page 261 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.
Download or read book MicroRNAs Novel Biomarkers and Therapeutic Targets for Human Cancers written by Takahiro Ochiya and published by MDPI. This book was released on 2018-10-16 with total page 273 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a printed edition of the Special Issue "MicroRNAs: Novel Biomarkers and Therapeutic Targets for Human Cancers" that was published in JCM
Download or read book Novel Biomarkers for Predicting Response to Cancer Immunotherapy written by Jinghua Pan and published by Frontiers Media SA. This book was released on 2023-07-11 with total page 493 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy.